Loading
A phase 1/2 trial of Trastuzumab and Ibrutinib in advanced solid tumours, run by US Oncology Research, active and no longer recruiting.
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT03379428 by US Oncology Research, with 34 participants enrolled, started 2017-11-29 and due to reach its primary completion in 2025-01. Interventions recorded: Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg and Ibrutinib 420 mg.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares McKesson / The US Oncology Network, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Ibrutinib, AbbVie (incl. ImmunoGen, Capstan), Small-molecule kinase inhibitors and the tag pipeline.
Shares Trastuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan), Monoclonal antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Trastuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/